The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8.

ABSTRACT: Tamoxifen, an important endocrine therapeutic agent, is widely used for the treatment of estrogen receptor positive (ER⁺) breast cancer. However, de novo or acquired resistance prevents patients from benefitting from endocrine approaches and necessitates alternative treatments. In this study, we report that small heat protein beta-8 (HSPB8) may serve as an important molecule in tamoxifen resistance. HSPB8 expression is enhanced in MCF-7 cells resistant to tamoxifen (MCF-7/R) compared to parent cells. Moreover, high expression of HSPB8 associates with poor prognosis in ER⁺ breast cancer patients but not in patients without classification. Stimulating ER signaling by heterogeneous expression of ERa or 17β-estradiol promotes HSPB8 expression and reduces the cell populati

SUBMITTER: Shi JJ 

PROVIDER: S-EPMC6289376 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature